| Manufacturing (CRAMS) | Process R&D, pilot scale manufacture, exclusive commercial manufacturing of APIs and formulations | Long-standing client relationships and expertise in CNS-related chemistries | Global pharma and fine chemical companies (B2B) | Custom synthesis and exclusive manufacturing contracts | 61387 | 92 | Project-based contracts and exclusive manufacturing agreements | Contractual sales and milestone-based payments | Rising pharma outsourcing, rapid scale-up capabilities, innovation in process development | Custom Synthesis, Clinical Trials Supplies |
| Services (Drug Discovery and Development Services - DDDSS) | Discovery, clinical development, and commercialization of novel CNS therapeutics | Robust IP portfolio and proprietary GPCR-targeted CNS therapies | Pharma companies and healthcare markets (B2B and B2C) | Clinical stage drug assets with IP ownership | 4988 | 7 | Licensing, royalties, clinical milestone payments | Milestone payments, royalties from out-licensing | Progression of clinical-stage candidates and licensing agreements | CNS Drug Candidates - Masupirdine, Samelisant |
| Research & Development | Innovative CNS drug discovery and preclinical research pipeline development | Strong R&D team focused on niche CNS therapeutic areas | Internal product development | N/A | 0 | 0 | Investment into future pipeline; no direct revenue | Capitalized R&D expenses | Ongoing clinical trials and innovation targeting CNS disorders | N/A |
